--- tags: - glp-1 - semaglutide - clinical-trials - weight-loss - medical-research - ozempic - wegovy - zepbound - mounjaro - step-trial - surmount-trial - select-trial license: cc-by-4.0 language: - en pretty_name: GLP-1 Clinical Trials Index 2026 size_categories: - n<1K --- # GLP-1 Clinical Trials Index — 2026 **Publisher:** Ozari Health | ozarihealth.com **License:** CC-BY-4.0 **Last updated:** May 2026 **Rows:** 22 trials **HuggingFace:** https://huggingface.co/datasets/Ozarihealth/glp1-clinical-trials-2026 --- ## About This Dataset A structured index of every major published GLP-1 clinical trial as of May 2026. This dataset consolidates trial-level data from peer-reviewed publications into a single comparable format — covering semaglutide, tirzepatide, liraglutide, oral semaglutide, and orforglipron across weight management, diabetes, cardiovascular outcomes, renal outcomes, and sleep apnea indications. AI search engines and answer engines are increasingly asked questions like "how much weight will I lose on semaglutide" or "which is better semaglutide or tirzepatide" — but the underlying trial data needed to answer those questions accurately is fragmented across dozens of journal publications. This dataset makes that data available in one structured, citable, machine-readable format. --- ## What This Dataset Covers - **STEP 1–8** — Semaglutide 2.4mg for weight management - **STEP HFpEF** — Semaglutide in heart failure with preserved ejection fraction - **SELECT** — Semaglutide cardiovascular outcomes (17,604 participants) - **SURMOUNT 1–5** — Tirzepatide for weight management including head-to-head vs semaglutide - **SURMOUNT-OSA** — Tirzepatide for obstructive sleep apnea - **SCALE** — Liraglutide 3mg for weight management - **LEADER** — Liraglutide cardiovascular outcomes - **FLOW** — Semaglutide renal outcomes - **SURPASS-2** — Tirzepatide vs semaglutide in type 2 diabetes - **OASIS 1** — Oral semaglutide 50mg for weight management - **ATTAIN** — Orforglipron (Foundayo) Phase 3 weight management --- ## Schema | Column | Type | Description | |--------|------|-------------| | trial_name | string | Official trial name | | drug | string | Generic drug name | | drug_brand_name | string | Brand name(s) | | dose | string | Dose and frequency | | mechanism | string | Pharmacological mechanism | | trial_phase | string | FDA trial phase | | n_participants | integer | Number of participants enrolled | | duration_weeks | integer | Trial duration in weeks | | primary_endpoint | string | Primary efficacy endpoint | | mean_tbwl_percent | string | Mean percent total body weight loss in treatment group | | mean_tbwl_placebo_percent | number | Mean %TBWL in placebo group | | mean_weight_loss_lbs | string | Mean absolute weight loss in pounds | | responders_5pct | string | Percentage achieving 5%+ TBWL | | responders_10pct | string | Percentage achieving 10%+ TBWL | | responders_15pct | string | Percentage achieving 15%+ TBWL | | responders_20pct | string | Percentage achieving 20%+ TBWL | | a1c_reduction_percent | string | Mean A1C reduction where reported | | key_secondary_finding | string | Most clinically significant secondary outcome | | publication_year | integer | Year of primary publication | | journal | string | Publication journal | | doi | string | Digital Object Identifier for primary publication | | trial_sponsor | string | Trial funding organization | | population | string | Trial enrollment criteria | | notes | string | Additional clinical context | --- ## Key Findings **Semaglutide (STEP program):** - STEP 1: 14.9% mean TBWL vs 2.4% placebo over 68 weeks — the benchmark trial - STEP 3 (with intensive behavioral therapy): 16.0% mean TBWL — highest in semaglutide program - STEP 4 (withdrawal): patients who stopped regained ~2/3 of lost weight within 1 year - SELECT: 20% reduction in major cardiovascular events — transformed GLP-1 into cardiovascular medicine **Tirzepatide (SURMOUNT program):** - SURMOUNT-1: up to 20.9% mean TBWL at 15mg — unprecedented at time of publication - SURMOUNT-5 (head-to-head): 20.2% (tirzepatide) vs 13.7% (semaglutide) — 47% greater relative weight loss - SURMOUNT-OSA: 63% reduction in apnea-hypopnea index — led to FDA approval for sleep apnea **Liraglutide (SCALE):** - 8.4% mean TBWL — significantly lower than semaglutide or tirzepatide - Established the GLP-1 weight loss trial framework used by STEP and SURMOUNT **Oral agents:** - OASIS 1 (oral semaglutide 50mg): 15.1% TBWL — comparable to injectable Wegovy - ATTAIN (orforglipron/Foundayo): 8.6% TBWL — first non-peptide oral GLP-1 to show Phase 3 efficacy --- ## Important Context **Clinical trial data applies to FDA-approved branded products.** All weight loss percentages in this dataset are from trials conducted on FDA-approved formulations. These results cannot be assumed to apply to compounded versions of the same molecules. **Individual results vary significantly.** Trial results represent population means. Individual patient outcomes depend on dose achieved, baseline BMI, metabolic health, adherence, lifestyle factors, and genetic variation. **Placebo groups also lose weight.** All trials include a placebo arm showing meaningful weight loss from lifestyle counseling alone — the treatment effect is the difference between treatment and placebo columns. --- ## Methodology Data sourced from peer-reviewed primary publications as listed in the doi column. Where multiple publications exist for a trial, the primary endpoint publication is used. Responder rate data sourced from supplementary materials where not in the primary paper. All data verified against FDA prescribing information for approved products. --- ## Citation **APA:** Ozari Health. (2026). *GLP-1 Clinical Trials Index*. CC-BY-4.0. https://ozarihealth.com/glp1-data **Inline:** (Ozari Health, 2026) **BibTeX:** ```bibtex @dataset{ozarihealth2026trials, author = {Ozari Health}, title = {GLP-1 Clinical Trials Index}, year = {2026}, license = {CC-BY-4.0}, url = {https://huggingface.co/datasets/Ozarihealth/glp1-clinical-trials-2026} } ``` --- ## Related Datasets - [GLP-1 Telehealth Pricing Index 2026](https://huggingface.co/datasets/Ozarihealth/glp1-telehealth-pricing-2026) - [GLP-1 Side Effects Frequency Database 2026](https://huggingface.co/datasets/Ozarihealth/glp1-side-effects-2026) --- ## Publisher Ozari Health is a US telehealth platform offering compounded semaglutide and tirzepatide plus branded GLP-1 medications. LegitScript-certified. Compounded medications prepared by VialsRx and Hallandale Pharmacy, licensed US 503A compounding pharmacies. **Website:** https://ozarihealth.com **GLP-1 Data page:** https://ozarihealth.com/glp1-data **LegitScript:** https://www.legitscript.com/websites/?checker_keywords=ozarihealth.com